---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-025848"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2024-07-01T23:59:59+00:00"
generated_at: "2026-05-31T23:54:14.485261+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elite Pharma FY2024 revenue $56.6M (+65% YoY); operating profit $10.8M (+192%)

## Summary
- Revenue of $56.6M, up $22.4M (65%) from prior fiscal year.
- Operating profit $10.8M, up $7.1M (192%) YoY.
- Net income attributable to common shareholders was $20.1M.
- Growth driven by commercial launch of Elite label product line in FY2024.
- Conference call on July 2, 2024 at 11:30 AM EDT for business update.

## SEC filing metadata
- accession: 0001493152-24-025848
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2024-07-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315224025848/0001493152-24-025848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315224025848/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-025848
- JSON: https://secwatch.observer/filing/0001493152-24-025848.json
- Plain text: https://secwatch.observer/filing/0001493152-24-025848.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.